[
  {
    "ts": "2026-02-23T12:00:00+00:00",
    "headline": "Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD",
    "summary": "SOMERVILLE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, its lead in vivo gene editing program. TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygous for the PiZ allele",
    "url": "https://finance.yahoo.com/news/tessera-therapeutics-receives-u-fda-120000512.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "4daa4c4e-6e8b-3245-87a2-62e8a93e1e40",
      "content": {
        "id": "4daa4c4e-6e8b-3245-87a2-62e8a93e1e40",
        "contentType": "STORY",
        "title": "Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD",
        "description": "",
        "summary": "SOMERVILLE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, its lead in vivo gene editing program. TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygous for the PiZ allele",
        "pubDate": "2026-02-23T12:00:00Z",
        "displayTime": "2026-02-23T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/46d96fc145b476370131e63d2f5c2958",
          "originalWidth": 1650,
          "originalHeight": 540,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Hr2bqINEsLQFkvPAefdlNQ--~B/aD01NDA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/46d96fc145b476370131e63d2f5c2958.cf.webp",
              "width": 1650,
              "height": 540,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jNEgtRBxc7pukElbitnnrw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/46d96fc145b476370131e63d2f5c2958.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tessera-therapeutics-receives-u-fda-120000512.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tessera-therapeutics-receives-u-fda-120000512.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]